PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.

Abstract Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy.
PMID
Related Publications

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.

Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.

Authors

Mayor MeshTerms
Keywords

Renal cell carcinoma

cancer registry

pazopanib

response

survival

Journal Title anticancer research
Publication Year Start




PMID- 29277808
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426
      Patients.
PG  - 449-456
AB  - BACKGROUND: Pazopanib is approved for the first-line treatment of patients with
      metastatic renal cell carcinoma (mRCC). The present study was a retrospective
      registry-based analysis of 426 patients with mRCC treated with pazopanib as
      first-line targeted therapy. PATIENTS AND METHODS: The data were obtained from
      the Renal Cell Carcinoma Information system registry. Patient baseline
      parameters, treatment course and outcomes, and toxicity were analysed. RESULTS:
      Median progression-free and overall survival were 12.9 (95% confidence
      interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. 
      Overall response rate and disease control rate were 25.1% and 57.4%,
      respectively. Adverse events led to discontinuation of treatment in 37 (12.1%)
      patients. CONCLUSION: The results confirm that pazopanib is an effective and safe
      first-line targeted treatment in patients with mRCC. Both the International mRCC 
      Database Consortium and the Memorial Sloan Kettering models were valid predictors
      of prognosis and nephrectomy was associated with improved survival.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Poprach, Alexandr
AU  - Poprach A
AD  - Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno,
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
FAU - Fiala, Ondrej
AU  - Fiala O
AD  - Department of Oncology and Radiotherapeutics, Faculty of Medicine and University 
      Hospital in Pilsen, Pilsen, Czech Republic.
AD  - Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen,
      Czech Republic.
FAU - Chloupkova, Renata
AU  - Chloupkova R
AD  - Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University,
      Brno, Czech Republic.
FAU - Melichar, Bohuslav
AU  - Melichar B
AD  - Department of Oncology, Palacky University Medical School and Teaching Hospital, 
      Olomouc, Czech Republic.
FAU - Lakomy, Radek
AU  - Lakomy R
AD  - Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno,
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
FAU - Petrakova, Katarina
AU  - Petrakova K
AD  - Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno,
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
FAU - Zemanova, Milada
AU  - Zemanova M
AD  - Department of Oncology, First Faculty of Medicine, Charles University and General
      University Hospital, Prague, Czech Republic.
FAU - Kopeckova, Katerina
AU  - Kopeckova K
AD  - Department of Oncology, Second Faculty of Medicine, Charles University and Motol 
      University Hospital, Prague, Czech Republic.
FAU - Slaby, Ondrej
AU  - Slaby O
AD  - Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno,
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
FAU - Studentova, Hana
AU  - Studentova H
AD  - Department of Oncology, Palacky University Medical School and Teaching Hospital, 
      Olomouc, Czech Republic.
FAU - Kopecky, Jindrich
AU  - Kopecky J
AD  - Department of Oncology, University Hospital in Hradec Kralove, Hradec Kralove,
      Czech Republic.
FAU - Kiss, Igor
AU  - Kiss I
AD  - Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno,
      Czech Republic.
AD  - Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
FAU - Finek, Jindrich
AU  - Finek J
AD  - Department of Oncology and Radiotherapeutics, Faculty of Medicine and University 
      Hospital in Pilsen, Pilsen, Czech Republic.
FAU - Dusek, Ladislav
AU  - Dusek L
AD  - Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen,
      Czech Republic.
FAU - Buchler, Tomas
AU  - Buchler T
AD  - Department of Oncology, First Faculty of Medicine, Charles University and
      Thomayer University Hospital, Prague, Czech Republic [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
RN  - EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - V99T50803M (sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology/surgery
MH  - Czech Republic
MH  - Databases, Factual
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Indoles/therapeutic use
MH  - Kidney Neoplasms/*drug therapy/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Nephrectomy
MH  - Proto-Oncogene Proteins c-kit/antagonists & inhibitors
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Pyrroles/therapeutic use
MH  - Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors
MH  - Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
MH  - Registries
MH  - Retrospective Studies
MH  - Sulfonamides/adverse effects/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Renal cell carcinoma
OT  - *cancer registry
OT  - *pazopanib
OT  - *response
OT  - *survival
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/01 00:00 [received]
PHST- 2017/11/01 00:00 [revised]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/449 [pii]
AID - 10.21873/anticanres.12243 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):449-456. doi: 10.21873/anticanres.12243.